Food, Nutrition & Wellness

Omega-3 Lowers 24-Hour Blood Pressure in Treated Patients, Small Trial Finds

17 November 2026, Buenos Aires, AR: Adding a daily omega-3 supplement to standard blood pressure and cholesterol medicines produced measurable falls in 24-hour blood pressure and in two blood markers of inflammation, according to a small randomized trial from Argentina published on November 9 in the peer-reviewed journal Nutrients. The investigators, led by Carol Kotliar and colleagues at the Santa Maria de la Salud Medical Center in Buenos Aires, describe the results as exploratory signals that need confirming in larger studies.

The trial enrolled 100 adults who were already being treated for both hypertension (high blood pressure) and dyslipidemia (unhealthy levels of blood fats such as cholesterol and triglycerides). Half were randomly assigned to take 2 grams a day of omega-3 fatty acids for 12 weeks, and half took a placebo made of medium-chain triglycerides, a type of fat not expected to affect blood pressure. Neither patients nor researchers knew who was receiving which capsule, and all participants stayed on their usual prescribed drugs. Of the 139 people screened, 100 were randomized and 46 in each group completed the study.

What the monitors picked up

The clearest differences showed up on ambulatory monitoring, in which patients wear a cuff that records blood pressure automatically through the day and night. Compared with placebo, the omega-3 group saw daytime systolic pressure (the upper number in a reading) fall by an additional 6.52 mmHg and nighttime diastolic pressure (the lower number) by an additional 5.55 mmHg. Central systolic pressure, an estimate of the pressure in the aorta close to the heart, fell 6.71 mmHg more than with placebo, although the authors note that this measure was available for only 28 participants.

Readings taken in the clinic, the conventional single measurement used in most doctors’ offices, showed no significant difference between the groups. That gap matters because ambulatory readings capture blood pressure across normal daily life and during sleep, and nighttime pressure in particular is regarded by cardiologists as a strong predictor of heart attacks and strokes.

Live Newsroom

24/7 Live Updates from Across the Globe

The researchers also tracked estimated pulse wave velocity, a gauge of how stiff the arteries are. It fell by 0.77 metres per second more in the omega-3 group. However, the value was calculated from a formula using age and blood pressure rather than measured directly between the neck and groin arteries, which is the reference method, so it largely mirrors the blood pressure changes rather than providing independent evidence.

On inflammation, the omega-3 group recorded a larger drop in the neutrophil-to-lymphocyte ratio, a simple count from a routine blood test that compares two types of white blood cell and rises when the body is under inflammatory stress. The ratio fell by 0.43 more than with placebo. Ferritin, a protein that stores iron and also climbs during inflammation, fell by 47.32 nanograms per millilitre more. High-sensitivity C-reactive protein, the inflammation marker most often used in cardiology, did not differ significantly between the groups.

Follow Global Agriculture on WhatsApp
Daily agribusiness news, straight to your phone
Follow Channel

Notably, the supplement produced no significant between-group change in triglycerides, LDL (“bad”) cholesterol, HDL (“good”) cholesterol or fasting blood glucose. Lowering triglycerides is the effect for which prescription omega-3 products are best known, though at doses usually higher than the 2 grams used here, and participants were already taking lipid-lowering medicines.

Limits the authors flag

The authors are explicit that the study was a pilot. Its statistical tests were not adjusted for the many outcomes examined, which raises the chance that some results arose by luck. The trial was also registered on the public database ClinicalTrials.gov (NCT06840964) retrospectively, in February 2025, rather than before the first patient was enrolled, a step that trial standards recommend to prevent outcomes being chosen after the data are seen. The authors conclude that independent replication in larger, prospectively registered trials is required before any clinical conclusions can be drawn.

According to the paper’s disclosures, the study received no external funding, and the Argentine drug maker Gador S.A. supplied the omega-3 and placebo capsules free of charge without any role in the design, analysis or reporting. The authors declare no conflicts of interest.

The findings arrive against a mixed evidence base. Large outcome trials of omega-3 supplements have produced conflicting results on heart attacks and strokes, and the benefit appears to depend heavily on dose and on the specific fatty acids used. Earlier pooled analyses of trials have generally found modest blood pressure reductions with omega-3 intake, larger in people with hypertension, but few studies have tested the supplements on top of existing drug treatment with round-the-clock monitoring, the gap this trial set out to address.

Demand for omega-3 products ties directly into marine and agricultural supply chains. Most of the long-chain omega-3 fats EPA and DHA sold as supplements come from fish oil, much of it rendered from small pelagic species such as anchovy caught off Peru and Chile, with algal oil and genetically engineered oilseed crops emerging as land-based alternatives. Interest in heart-health applications feeds into that demand, and the Buenos Aires team’s results, if borne out in larger trials, would add a specific use case: patients whose blood pressure is already treated but not fully controlled across the day and night.

For now, the measured improvements were confined to ambulatory and estimated measures over 12 weeks in 92 patients who finished the study, with conventional clinic readings and standard cholesterol tests unchanged.

Also Read: ADM Opens New Destination Marketing Office in Nairobi, Strengthening Presence Across East Africa

Global Agriculture is an independent international media platform covering agri-business, policy, technology, and sustainability. For editorial collaborations, thought leadership, and strategic communications, write to pr@global-agriculture.com